Anti-PVR/CD155 Antibody, clone SKII.4 ZooMAb® Mouse Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone SKII.4 is ZooMAb® mouse recombinant monoclonal antibody that specifically detects Poliovirus receptor (PVR/CD155). It targets an epitope within the extracellular domain.
• Immunogen: SK-N-S1 human neuroblastoma cells.
• Application: Quality Control TestingEvaluated by Immunocytochemistry in HeLa cells.Immunocytochemistry Analysis: A 1:100 dilution of this antibody detected PVR/CD155 in HeLa cells.Tested ApplicationsFlow Cytometry Analysis: 0.1 µg from a representative lot detected PVR/CD155 in one million Hela cells.Affinity Binding Assay: A representative lot of this antibody bound His-tagged recombinant fragment corresponding to the extracellular domain of Human PVR/CD155 with a KD of 1.4 x 10-6 in an affinity binding assay.Enzyme Immunoassay Analysis (ELISA): A serial of dilutions from a representative lot detected His-tagged recombinant fragment corresponding to the extracellular domain of Human PVR/CD155.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
• Target description: Poliovirus receptor (UniProt: P15151; also known as Nectin-like protein 5, NECL-5, CD155) is encoded by the PVR (also known as PVS) gene (Gene ID: 5817) in human. CD155 is a single-pass type I, N-glycosylated, membrane protein that mediates NK cell adhesion and triggers NK cell effector functions. It is ubiquitously expressed, and many human tumors are reported to significantly upregulate its expression. It binds two different NK cell receptors: CD96 and CD226 and these interactions accumulate at the cell-cell contact site, leading to the formation of a mature immunological synapse between NK cell and the target cell. This may trigger adhesion and secretion of lytic granules and IFN-γ and activate cytotoxicity of activated NK cells. CD155 serves as a receptor for poliovirus and may play a role in axonal transport of poliovirus by targeting virion-PVR-containing endocytic vesicles to the microtubular network through interaction with dynein light chain Tctex-type 1 (DYNLT1). It is synthesized with a signal peptide (aa 1-20), which is subsequently cleaved off to generate the mature form that contains an extracellular domain (aa 21-343), a transmembrane domain (aa 344-367), and a cytoplasmic domain (aa 368-417). It contains two Ig-like C2 type domains (aa 145-237 and 233-328), and an Ig-like V-type domain that is shown to be necessary and sufficient for virus binding and uptake. CD155 also has one the immunoreceptor tyrosine-based inhibitor motif (ITIM; aa 396-401) that when phosphorylated by Src kinases binds to the SH2 domain of several SH2-containing phosphatases. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, Affinity™, reproducibility, and stability over conventional monoclonals. (Ref.: Sloan, KE., et al. (2004). BMC Cancer. 4; 73; Oda, T., et al. (2004). Biochem. Biophys. Res. Commun. 319(4);1253-1264; Mendelsohn, CL., et al. (1989). Cell. 56(5); 855-865).
• Physical form: Purified recombinant mouse monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
• Reconstitution: 300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: Affinity is a trademark of Mine Safety Appliances Co.
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.